Lv2
170 积分 2026-01-27 加入
Survival Analysis of the WSG TP-II Trial: Neoadjuvant Trastuzumab and Pertuzumab Plus Endocrine Therapy Versus Chemotherapy in Hormone Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Positive Early Breast Cancer
1个月前
已完结
Preclinical characterization and phase 1 results of TQB2102, a first-in-class HER2 biparatopic antibody-drug conjugate, in patients with advanced solid tumors
1个月前
已关闭
Survival Analysis of the WSG TP-II Trial: Neoadjuvant Trastuzumab and Pertuzumab Plus Endocrine Therapy Versus Chemotherapy in Hormone Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Positive Early Breast Cancer
1个月前
已完结
Bone metastases diminish extraosseous response to checkpoint blockade immunotherapy through osteopontin-producing osteoclasts
1个月前
已完结
Denosumab Compared With Zoledronic Acid for the Treatment of Bone Metastases in Patients With Advanced Breast Cancer: A Randomized, Double-Blind Study
1个月前
已完结
Vepdegestrant, a PROTAC Estrogen Receptor Degrader, in Advanced Breast Cancer
2个月前
已完结
The Curious Incident of the T-DXd Arm Killed at (DESTINY-Breast) Eleven O'Clock: Statistical Concerns
3个月前
已关闭
Efficacy and Safety of Solifenacin Succinate Tablets Versus Solifenacin Succinate Tablets With Local Oestrogen for Overactive Bladder in Post-Menopausal Women – A Multi-Centre, Randomised, Open, Controlled Comparison Study
3个月前
已关闭
Datopotamab deruxtecan in patients with untreated, advanced triple-negative breast cancer (TROPION-Breast02): a randomised, open-label, international, phase III trial
3个月前
已完结
Targeting the glucocorticoid receptor as a therapeutic strategy for ovarian cancer: The ROSELLA study
3个月前
已完结
皖公网安备34019202002308
